Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs ORY 2001 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms SATEEN
- Sponsors Oryzon
- 10 Nov 2017 Status changed from planning to recruiting.
- 02 Nov 2017 New trial record
- 31 Oct 2017 According to an Oryzon media release, the company has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS).